Avapritinib treatment of KIT D816V-mutant atypical chronic myeloid leukemia.

ABSTRACT:

Background

Atypical chronic myeloid leukemia (aCML) is a rare myelodysplastic/myeloproliferative neoplasm. There is no proven standard of care treatment and the only curative option available is hematopoietic stem cell transplant. In addition to traditional chemotherapy, targeted therapy has shown to be a promising. Avapritinib is a selective type 1 tyrosine kinase inhibitor with high potency for KIT D816V and was recently approved for treatment of systemic mastocytosis. Here we present a case of aCML with novel D816V mutation treated with avapritinib for 17 months leading to clonal extinction of the driver mutation.

Case presentation

An 80 year old man initially presented for evaluation of aCML. A bone marrow biopsy was completed, and next generation sequencing was notable

SUBMITTER: Sandow L 

PROVIDER: S-EPMC10248858 | biostudies-literature | 2023

REPOSITORIES: biostudies-literature